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Global Subcellular Characterization of Protein
Degradation Using Quantitative Proteomics*□S
Mark Larance‡, Yasmeen Ahmad‡, Kathryn J. Kirkwood‡, Tony Ly‡,
and Angus I. Lamond‡§¶
Protein degradation provides an important regulatory
mechanism used to control cell cycle progression and
many other cellular pathways. To comprehensively ana-
lyze the spatial control of protein degradation in U2OS
osteosarcoma cells, we have combined drug treatment
and SILAC-based quantitative mass spectrometry with
subcellular and protein fractionation. The resulting data
set analyzed more than 74,000 peptides, corresponding to
5000 proteins, from nuclear, cytosolic, membrane, and
cytoskeletal compartments. These data identified rapidly
degraded proteasome targets, such as PRR11 and high-
lighted a feedback mechanism resulting in translation in-
hibition, induced by blocking the proteasome. We show
this is mediated by activation of the unfolded protein
response. We observed compartment-specific differ-
ences in protein degradation, including proteins that
would not have been characterized as rapidly degraded
through analysis of whole cell lysates. Bioinformatic anal-
ysis of the entire data set is presented in the Encyclo-
pedia of Proteome Dynamics, a web-based resource,
with proteins annotated for stability and subcellular
distribution. Molecular & Cellular Proteomics 12:
10.1074/mcp.M112.024547, 638–650, 2013.
Targeted protein degradation is an important regulatory
mechanism that allows co-ordination of cellular pathways in
response to environmental and temporal stimuli (1). The con-
trol of diverse biochemical pathways, including cell cycle
progression and the response to DNA damage, is mediated,
at least in part, by dynamic alterations in protein degradation
(2). Previous large scale proteomics studies in mammalian
cells have shown that the rate of protein degradation can vary
from the timescale of minutes, to essentially infinite stability
for metastable proteins (3–8).
Most intracellular proteins have similar degradation rates,
with a half-life approximating the cell doubling rate. Under 5%
of proteins display degradation rates more than threefold
faster than the proteome average (3–5, 7). However, degra-
dation rates for individual proteins can change, for example
depending on either the cell cycle stage, or signaling events,
and can also vary depending on subcellular localization. Dis-
ruption of such regulated protein stability underlies the dis-
ease mechanisms responsible for forms of cancer, e.g. p53 (9,
10) and the proto-oncogene c-Myc (11).
Detection of rapidly degraded proteins can be difficult be-
cause of their low abundance. However, advances in mass
spectrometry based proteomics have enabled in-depth quan-
titative analysis of cellular proteomes (12–14). Stable isotope
labeling by amino acids in cell culture (SILAC)1 (15), has been
widely used to measure protein properties such as abun-
dance, interactions, modifications, turnover, and subcellular
localization under different conditions (16). Subcellular frac-
tionation and protein size separation are also powerful tech-
niques that enhance in-depth analysis of cellular proteomes.
Not only do these fractionation techniques increase total pro-
teome coverage, they also provide biological insight regarding
how protein behavior differs between subcellular compart-
ments. For example, subcellular fractionation has highlighted
differences in the rate of ribosomal protein degradation be-
tween the nucleus and cytoplasm, (7, 17). Other studies have
also demonstrated the benefit of in-depth subcellular fraction-
ation and created methods for the characterization of how
proteomes are localized in organelles (18–20).
In this study we have used SILAC-based quantitative mass
spectrometry combined with extensive subcellular and pro-
tein-level fractionation to identify rapidly degraded proteins in
human U2OS cells. We provide a proteome level character-
ization of a major feedback mechanism involving inhibition of
protein translation when the proteasome is inhibited. We also
present the Encyclopedia of Proteome Dynamics, a user-
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friendly online resource providing access to the entire data
set.
EXPERIMENTAL PROCEDURES
Materials—U2OS cells were purchased from the American Type
Culture Collection (ATCC, Rockville, MD). Dulbecco’s modified Eagle
medium (DMEM), fetal calf serum, antibiotics, NuPage gels, LDS
sample buffer, MES SDS-PAGE running buffer, nitrocellulose iBlot
stacks, SYPRO Ruby, Alexa Fluor 680-conjugated secondary anti-
bodies, and CBQCA assay kit were obtained from Invitrogen (Carls-
bad, CA). IrDye 800-conjugated secondary antibodies were obtained
from Rockland Immunochemicals (Gilbertsville, PA). HRP-conjugated
secondary antibodies were from Cell Signaling Technology (Danvers,
MA). bicinchoninic acid (BCA) assay reagents, Coomassie plus (Brad-
ford) reagent, subcellular protein fractionation Kit, detergent removal
plates, 16% methanol-free paraformaldehyde, Acclaim Pepmap C18
columns and trapping cartridges, and triscarboxyethylphosphine
(TCEP) (Bond-breaker neutral pH solution) were from Thermo Scien-
tific (Waltham MA). Trypsin Gold was from Promega. Sep-Pak tC18
96-well -elution plates were from Waters (Milford, MA). Complete
protease inhibitor mixture tablets and PhosStop phosphatase inhibi-
tor tablets were from Roche (Basel, Switzerland). All other materials
were obtained from Sigma (St. Louis, MO).
Cell Culture—Briefly, U2OS cells were grown in DMEM supple-
mented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/l
penicillin, and 100 g/l streptomycin at 37 °C in 10% CO2, and
passaged at 80% confluence. For SILAC labeling of U2OS cells
arginine and lysine free DMEM was used and supplemented with
stable isotope labeled arginine and lysine in addition to dialyzed FCS
as described previously (21). After splitting by trypsinization, cells in
SILAC media were grown to 80% confluence over 2–3 days before
drug treatment and lysis for fractionation.
Subcellular Fractionation of SILAC-Labeled U2OS Cells—For the
SILAC screen U2OS cells were treated with either DMSO, 40 g/ml
cycloheximide or 10 M MG132 for 6 h and then combined in a 1:1:1
ratio of cells and fractionated by detergent solubility with the subcel-
lular protein fractionation kit (Pierce). These fractions were then chlo-
roform-methanol precipitated (22) and further separated by molecular
weight using denaturing size exclusion chromatography before diges-
tion and liquid chromatography-tandem MS (LC-MS/MS) analysis.
Denaturing Size Exclusion Chromatography (SDS-SEC), Trypsin
Digestion, and Peptide Clean-up—Using a Dionex Ultimate 3000
HPLC system, fractions resuspended in 4% SDS, 100 mM NaCl, 25
mM TCEP, 50 mM N-ethylmaleimide, 10 mM Na PO4 pH 6.0 were
heated to 65 °C for 10 min, then filtered through a 0.45 m filter.
Samples were injected (50 l per injection - 250 g protein) onto a
mAbPacSEC column (Dionex) equilibrated with 0.2% SDS, 100 mM
NaCl, 10 mM Na PO4 pH 6.0. The flow rate was 0.2 ml min
1 and 8 
200 l fractions were collected using a low protein binding 96-deep
well plate (Eppendorf). Triethylamine bicarbonate (TEAB, 1 M pH 8.0)
was added to each fraction to adjust the pH to 8.0, and trypsin diluted
in 0.1 M TEAB was added at a ratio of 1:50 with incubation for 18 h at
37 °C. SDS was removed from each fraction using detergent removal
resin in 96-well plates as described previously (23). For peptide de-
salting trifluoroacetic acid (TFA) was added to 1% (v/v) final concen-
tration and peptides were purified using a Sep-Pak tC18 96-well
-elution plate. Peptides were eluted in 200 l of 50% (v/v) acetoni-
trile 0.1% TFA and speedivaced to dryness before resuspension in
5% (v/v) formic acid. Peptide concentrations were determined using
the CBQCA assay after 25-fold dilution of peptide samples in 0.1 M
borate buffer pH 9.3.
LC-MS/MS and MS Data Analysis—Using a Dionex Ultimate 3000
nanoHPLC system, 4 g of peptides in 5% (v/v) formic acid were
injected onto an Acclaim PepMap C18 nano-trap column (Dionex).
After washing with 2% (v/v) acetonitrile 0.1% (v/v) formic acid pep-
tides were resolved on a 50 mm  75 m Acclaim PepMap C18
reverse phase analytical column over a 140 min organic gradient with
a flow rate of 200 nl min1. Peptides were ionized by nano-electros-
pray ionization at 1.2 kV using a fused silica emitter with an internal
diameter of 5 m (New Objective). Tandem mass spectrometry anal-
ysis was carried out on a QExactive mass spectrometer (Thermo
Scientific). Data were processed, searched, and quantified using the
Maxquant software package version 1.2.2.5 as described previously
(24, 25), using the default settings and employing the Human Uniprot
database (06/07/11) containing 109,824 entries. The settings used for
the Maxquant analysis were: two failed cleavages were allowed; fixed
modification was N-ethylmaleimide on cysteine; enzymes were Tryp-
sin (K/R not before P); Variable modifications included in the analysis
were methionine oxidation, deamidation of glutamine or asparagine,
N-terminal pyro-glutamic acid formation, protein N-terminal acetyla-
tion. A mass tolerance of 7 ppm was used for precursor ions and a
tolerance of 20 ppm was used for fragment ions. Using the default
Maxquant settings a maximum false positive rate of 1% was allowed
for both peptide and protein identification. This cutoff was used for
accepting individual spectra as well as whole proteins in the Max-
quant output. This threshold has previously been shown to be a
rigorous method for identifying true positive matches (24). For iden-
tical protein matches in both Swissprot and Tremble within the
same protein group, the match in Swissprot was reported. Isoforms
were recorded in the same protein group if they shared the same
peptide coverage. All replicates indicated are biological replicates
and protein quantitation was derived from at least two of the
biological replicates. SILAC ratios for all proteins were normalized
using -Tubulin, Histone H2A, and GAPDH ratios. No outlier data
points were removed.
Statistical Analysis of SILAC Data—p values were calculated using
a Student’s t test comparing the three biological replicate SILAC
ratios of each protein, to the three biological replicate SILAC ratios for
the control, known stable proteins, i.e. -tubulin, histone H2A, and
GAPDH. For the CHX/DMSO (M/L) and MG132/DMSO (H/L) SILAC
ratios a one-tailed and two-tailed t test was used respectively. Values
were tested for normality using the Shapiro-Wilk test.
SDS-PAGE and Immunoblotting—For generating total cell lysates,
cells were lysed in five times the total volume of cells using 2% SDS
in 10 mM HEPES, 250 mM sucrose, and 1 mM EDTA (HES buffer) with
50 mM N-ethylmaleimide, Complete Protease Inhibitors EDTA-free
(Roche) and PhosStop (Roche). Lysates were incubated at 65 °C and
viscosity because of DNA was removed by passing the lysate through
a Qiashredder (Qiagen). Equal amounts of protein were loaded for
SDS-PAGE of each sample with 10 g per lane. SDS-PAGE was
performed using 4–12% (w/v) Bis-Tris NuPage gels using MES run-
ning buffer according to manufacturer’s instructions but with the
addition of 25 mM TCEP, in the LDS sample buffer. SYPRO Ruby
staining was performed as per manufacturer’s instructions (Invitro-
gen). For Western blotting, separated proteins were electrophoreti-
cally transferred to an iBlot nitrocellulose membrane, blocked with
3% nonfat skim milk in 0.1% Tween-20 in TBS (TBST) and incu-
bated with primary antibody in 5% bovine serum albumin (BSA) in
TBST overnight at 4 °C. After incubation, membranes were washed
three times in TBST and incubated with either HRP-labeled or Alexa
fluor 680/IrDye 800 labeled secondary antibodies in 3% nonfat skim
milk in TBST. Proteins were visualized using Immobillon chemilu-
minescent substrate (Millipore) and imaged either with a cooled
CCD camera (Fuji) for HRP-labeled secondary antibodies, or a Licor
Odyssey CLx imager for Alexa fluor 680/IrDye 800 labeled second-
ary antibodies.
Immunofluorescence Microscopy—Cells were cultured on glass
coverslips as described above. All subsequent steps are at 25 °C.
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Cells were then fixed with 3% paraformaldehyde in PBS. Fixed cells
were washed with PBS, and free aldehyde groups were quenched
with 50 mM glycine in PBS. The cells were then permeabilized using
1% Triton X-100 for 10 min followed by washing in PBS. Coverslips
were processed for immunolabeling by blocking with 5% BSA in
TBST. Primary antibodies were incubated on coverslips for 1 h in 5%
BSA in TBST. Coverslips were washed in PBS. Primary antibodies
were detected with Alexa Fluor 488 or Alex Fluor 594 conjugated
secondary antibodies which were incubated on coverslips for 30 min
in 5% BSA in TBST with 2 g/ml Hoechst 33342. Optical sections
were analyzed by confocal microscopy on a Leica SP2 AOBS inverted
microscope. Images generated are a single confocal slice from the
middle of the cell monolayer.
siRNA Transfection of U2OS Cells—U2OS cells were transfected
with 0.45 nmoles of siRNA per condition using RNAiMax (Invitrogen)
in Optimem medium (Invitrogen). After 24 h, cells were harvested by
trypsinization for analysis either by SDS-PAGE or flow cytometry.
Fluorescence-activated Cell Sorting (FACS)—An asynchronous
U2OS cell suspension in DMEM containing 10% FCS was incu-
bated with 25 g/ml Hoechst 33342 for 5 min at room temperature.
Cells were sorted by DNA content into G1, S and G2-phase cell
populations using an ACS Vantage DIVA instrument (BD Biosci-
ences). Sorted cells were washed in PBS and lysed in 2% SDS in
HES buffer.
RESULTS
Workflow for the Identification of Rapidly Degraded Pro-
teins—To identify rapidly degraded proteins human U2OS
osteosarcoma cells were treated for 6 h with cycloheximide
(CHX), which rapidly blocks translation elongation and hence
protein synthesis. This method has been used in many studies
of protein degradation (26) and is complementary to previous
studies using pulse-SILAC to identify rapidly degraded pro-
teins (3, 6, 7). To determine if rapidly degraded proteins are
substrates of the ubiquitin-proteasome system a separate
population of U2OS cells were treated for 6 h with the pro-
teasome inhibitor MG132. As a control, U2OS cells were
treated with DMSO for 6 h. The DMSO control, cycloheximide,
and MG132 treated cells were grown, respectively, in either
“light,” “medium,” or “heavy” SILAC media (Fig. 1A; see
methods). After the 6 h incubation, the three cell populations
were mixed in equal amounts and processed for MS analysis
as described below (Fig. 1A).
The resulting isotope-encoded proteins isolated from the
mixed-cell populations were fractionated both by subcellular
compartment and molecular weight (Fig. 1A). Four subcellular
fractions were generated, i.e. nucleus, cytosol, cytoskeleton,
and membrane. Each subcellular fraction was individually
separated by protein molecular weight, using denaturing SDS
size exclusion chromatography (SDS-SEC), as previously de-
scribed (27, 28). Proteins were digested with trypsin and
analyzed by LC-MS/MS. Three biological replicates of this
experiment were performed.
Peptides were identified and SILAC ratios quantitated using
MaxQuant (24, 25). A total of over 74,000 peptides, corre-
sponding to5,000 proteins, were identified and quantified in
at least two out of the three biological replicates (supplemen-
tal Table S1 and supplemental Table S2). The 5000 proteins
analyzed in this study are highly representative of the human
proteome, based on an analysis of amino acid frequencies
and gene ontology (biological process) term frequencies in the
total dataset (supplemental Fig. S1A, S1B). Analysis of the
subcellular distribution of selected marker proteins known to
be enriched in the isolated compartments (Fig. 1B), confirmed
80% enrichment of each fraction. For each subcellular frac-
tion, proteins with masses from 500 kDa down to 10 kDa
were efficiently size-separated using SDS-SEC (Fig. 1C).
Characterization of Rapidly Depleted Proteins—The work-
flow outlined above will detect rapidly depleted proteins
(RDPs), whose abundance decreases following cyclohexi-
mide treatment, either because of degradation, or secretion.
To identify RDPs with high statistical significance, p values
were calculated using a t test of the replicate CHX/DMSO
(M/L) SILAC ratios of each protein, compared with the CHX/
DMSO (M/L) SILAC ratios for control, known stable proteins,
i.e. -Tubulin, Histone H2A, and GAPDH. A significance cutoff
value of p  0.05 (-Log10(p)  1.3) was used, combined with
a requirement of a 50% decrease in CHX/DMSO (M/L)
SILAC ratio (Log2 normalized ratio CHX/DMSO  1), indi-
cating at least 50% depletion in less than 6 h.
These criteria yielded 110 RDPs out of the total data set of
5000 proteins (Fig. 2a green box, and supplemental Table
S3). This included proteins previously shown to be rapidly
degraded, such as p21 (29), the MORF4L1, and MRFAP1
proteins (28), and Jun-B (30) (Fig. 2A, green text). Some
RDPs showed different degradation rates in separate sub-
cellular compartments (supplemental Fig. S2), demonstrat-
ing that individual protein stability can vary depending on
localization.
Rapidly Depleted Proteins Vary Between Subcellular Com-
partments—The same significance cutoffs (p  0.05 and
50% decrease in CHX/DMSO M/L SILAC ratio), were used
to analyze the data from each subcellular fraction (Fig. 2B).
This identified an additional subset of proteins whose abun-
dance rapidly decreased in a specific compartment, but
which were not identified as RDPs in the total data set
(Fig. 2a,b). C7ORF59, FAM32A, PLOD3 and GLT25D1, pro-
vide clear examples of proteins not detected as statistically
significant RDPs in the total data set, but where analysis of
data from a single subcellular fraction show they behave as
compartment-specific RDPs (Fig. 2A, 2B blue points and see
supplemental Table S1 for more examples). These examples
illustrate that this phenomenon is not confined to any one
fraction alone and further show it applies to proteins detected
in multiple locations and not only to proteins enriched in a
single compartment. For most of the compartment specific
RDPs, reciprocal increases in CHX/DMSO (M/L) ratios were
not seen in other fractions, indicating that decreased abun-
dance results from degradation and secretion, rather than
from intracellular trafficking between compartments (supple-
mental Table S1).
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Comparative Analysis of RDPs—The RDPs identified were
analyzed for sequence motifs involved in targeted degrada-
tion mechanisms (supplemental Table S3) and compared with
data from two recent large scale (5000 proteins detected),
pulse-SILAC analyses of protein turnover in either HeLa cells
(7), or mouse NIH-3T3 cells (6). We have also examined the list
FIG. 1. Global protein degradation analysis using a comprehensive proteomics workflow. A, Workflow for SILAC-based quantitative
mass spectrometry to identify rapidly degraded proteins. B, The subcellular fractionation for the SILAC-screen was assessed using marker
proteins of known localization. The markers included GAPDH, -Tubulin, and hexokinase-2 (cytosolic fraction), citrate synthase, syntaxin-4,
syntaxin-7, rab-4b, and LAMP-1 (membrane fraction), histone H2A and MORF4L1 (nuclear fraction), vimentin and keratin-10 (cytoskeletal
fraction). The percentage of total protein is indicated on the y axis. The colors indicate percentages in each fraction. C, Analysis of protein
SDS-SEC fractionation versus the predicted protein molecular weights based on an in silico translation of the human genome. The average
fraction for protein detection in the SILAC-screen is shown on the y axis. The x axis shows the log2 scaled predicted protein molecular weights.
Subcellular Characterization of Protein Degradation
Molecular & Cellular Proteomics 12.3 641
FIG. 2. Identification of rapidly depleted proteins. A, The analysis of 5000 proteins is indicated with the mean ratio from three replicates
of each protein, represented by a black spot (n  3). The y axis shows a p value (-log10 transformed) derived from a t test across the three
biological replicates for each protein, compared with the biological replicates of negative control proteins, which do not display rapid depletion.
The relative fold change is shown on the x axis using the log2 ratio cycloheximide/DMSO (Medium/Light). Proteins with a p  0.05 and a fold
change -1 are overlaid by the green box and we define these as rapidly depleted proteins (RDPs). Examples of previously uncharacterized
proteins highlighted in this study are marked in red and proteins regarded as positive controls are marked in green. B, The analysis of proteins
found in each subcellular fraction is shown with the mean ratio from three replicates of each protein represented by a black spot (n  3). The
y axis shows a p value (-log10 transformed) derived from a t test across the three biological replicates for each protein, compared with the
biological replicates of negative control proteins, which do not display rapid depletion. The relative fold change is shown on the x axis using
the log2 ratio cycloheximide/DMSO (Medium/Light). Proteins with a p 0.05 and a SILAC ratio-1 are overlaid by the green box and we define
these as fraction-specific rapidly degraded proteins (RDPs).
Subcellular Characterization of Protein Degradation
642 Molecular & Cellular Proteomics 12.3
of RDPs to mark previously known and predicted secreted
proteins (supplemental Table S3) (31), which rapidly decrease
in relative abundance after cycloheximide treatment because
of protein secretion, rather than degradation. Mitochondrial
targeting of the RDPs using either motif-based prediction or
previous localization data has also been annotated for each
protein (supplemental Table S3) (31).
Many of these novel RDPs contain known degradation tar-
geting motifs, such as Anaphase Promoting Complex (APC/C)
KEN-boxes (32, 33), APC/C D-boxes (33, 34), and Skp1-Cul-
lin-Fbox (SCF) FBXW7-binding sites (35, 36) (supplemental
Table S3). These motifs are found in many proteins whose
abundance is regulated during the cell cycle by rapid degra-
dation at specific stages (2). Comparison of all the 110 RDPs
identified in this study with data from the previous large scale
mammalian protein turnover studies, showed that 34% of
our new RDP data were not reported in the earlier studies
(supplemental Table S3). Of those RDP proteins previously
detected in at least one of the former studies, 70% were also
found to be rapidly degraded in the mouse NIH-3T3 data (61
proteins detected in common) and 59% were also rapidly
degraded in the HeLa data (37 proteins detected in common).
The fact that not all of our RDPs were detected as being
rapidly turned over in each of these previous large scale
studies may reflect differences in both the cell types and
organisms analyzed.
Proteasome Inhibition Triggers the Unfolded Protein Re-
sponse—The total proteome data set and the subset of 110
RDPs were examined for their response to the proteasome
inhibitor MG132 (Fig. 3A, 3B and supplemental Table S1).
Interestingly, in both cases 1% of proteins showed a signif-
icant change in abundance after proteasome inhibition, i.e.
either increase, or decrease, greater than twofold with p 
0.05, after MG132 treatment. To confirm that the MG132
treatment effectively blocked the proteasome, we analyzed
our total data set for the abundance of K48-linked ubiquitin
and histone H2A ubiquitin conjugates, which were previously
shown to change following proteasome inhibition (37). This
showed that MG132 treatment significantly increased the
abundance of K48-linked ubiquitin conjugates and signifi-
cantly decreased the levels of histone H2A-ubiquitin conju-
gates (supplemental Fig. S3A), confirming proteasome inhibi-
tion. Within our total data set, many of the proteins that
significantly increase in abundance after MG132 treatment
are associated with induction of the unfolded protein re-
sponse (UPR), including ATF3, SERPINH1, HSF2, and
HSP90AB1 (Fig. 3A). To further investigate the MG132-medi-
ated activation of the UPR, we immunoblotted total cell ly-
sates of U2OS cells after 6 h of MG132 treatment to test for
phosphorylation of eIF2alpha, which is known to be induced
during the UPR (38). This confirmed an increased abundance
of phospho-serine51 on eIF2alpha following treatment with
MG132, which is inhibitory for translation (supplemental Fig.
S3B). Many of the proteins that significantly decrease after
MG132 treatment are RDP proteins that are either predicted
to be secreted (e.g. collagen COL1A1), or to have mitochon-
drial (e.g. CHCHD2), or integral membrane localization (e.g.
GOLM1). These data therefore indicate which of the RDPs are
likely to be proteasome targets, i.e. the subset of RDPs whose
abundance does not change significantly after MG132
treatment.
Analysis of Novel RDPs—Four novel RDPs were selected
for further characterization, based on the data in supplemen-
tal Table S3 and on the availability of antibody reagents i.e.
(Proline-rich protein 11, PRR11; Coiled-coil-helix-coiled-coil-
helix domain-containing protein 2, CHCHD2; uncharacterized
protein, C20ORF43; and Myeloid leukemia factor 2, MLF2)
(Fig. 2A and Fig. 3A, 3B red points). Our MS data show that
while all four of these proteins decreased in abundance after
protein synthesis inhibition, three (PRR11, C20ORF43, and
MLF2) showed no significant change after MG132 treatment,
consistent with them being proteasome targets, whereas
CHCHD2 decreased in abundance (Fig. 3A, 3B). None of
these proteins significantly increased in abundance when the
proteasome was inhibited. Next, therefore, we analyzed their
degradation using a complementary Western blotting method
(Fig. 3C).
U2OS total cell lysates, treated either with a time course of
cycloheximide alone, or cycloheximide used in combination
with MG132, were immunoblotted using specific antibodies
for the CHCHD2, PRR11, C20ORF43, and MLF2 proteins
(Fig. 3C). These data showed all four proteins decreased in
abundance to a similar extent as observed in the SILAC exper-
iments after cycloheximide treatment alone. This indepen-
dently confirms that all four factors are RDPs. These experi-
ments also showed that PRR11, C20ORF43, and MLF2 were
protected from degradation by adding MG132 together with
cycloheximide, indicating that they are proteasome targets.
However, CHCHD2 was not protected by MG132 and still de-
creased in abundance with similar kinetics to adding cyclohex-
imide alone. Therefore, CHCHD2 is likely to be degraded by a
proteasome-independent mechanism.
PRR11 is Cell Cycle Regulated—Detection of the PRR11
protein in the immunoblot was validated by siRNA knock-
down of PRR11 mRNA (supplemental Fig. S3C). Quantitation
of the blotting data showed that PRR11 disappeared expo-
nentially after cycloheximide addition, but was stabilized by
simultaneous MG132 treatment of the U2OS cells (Fig. 3D).
The PRR11 protein is previously uncharacterised but contains
multiple highly conserved sequence motifs associated with
cell cycle regulated protein degradation (Fig. 4A and Sup the
plemental Table S3). We therefore tested whether the abun-
dance of PRR11 varies during the cell cycle.
First, the specific PRR11 antibody was used to characterize
PRR11 expression and localization in U2OS cells by confocal
immunofluorescence microscopy (supplemental Fig. S4). This
showed that PRR11 staining was predominantly cytoplasmic
and varied in intensity between cells, as compared with vi-
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mentin, which showed similar levels of staining in all of the
cells. To test whether cell to cell variation in intensity of PRR11
staining reflects cell cycle modulation of its abundance, we
used fluorescence-activated cell sorting (FACS) analysis of
live U2OS cells, based on DNA content, to yield asynchro-
nous, G1, S, and G2/M phase cell populations. The cell pop-
ulations were lysed and immunoblotted with the PRR11 anti-
body (Fig. 4B). This showed that PRR11 levels increased from
G1 to G2/M-phase cells. These data demonstrate that the
levels of PRR1 protein vary during the cell cycle.
Computational Analysis of the Rapidly Degraded Pro-
teins—To enable convenient access to the wealth of quanti-
tative proteomics data generated in this study, we have de-
veloped the Encyclopedia of Proteome Dynamics (http://
www.peptracker.com/encyclopediaInformation/,). This is an
online resource that collates all of the protein data from this
study, together with data from our other recent proteomics
studies, in a publicly available database, (Fig. 5A). Using this
database we have analyzed the subset of total proteins iden-
tified as RDPs for biological process GO term enrichment,
with a significance threshold of p 0.01 when compared with
an in silico translation of the human proteome (Fig. 5B). This
showed that GO terms including regulation of cell cycle, mi-
tosis, response to DNA damage stimulus, macromolecular
FIG. 3. Analysis of the proteome-wide response to proteasome inhibition. A, The analysis of 5000 proteins is indicated with the mean
ratio from three replicates of each protein represented by a black spot (n  3). The y axis shows a p value (-log10 transformed) derived from
a t test across the three biological replicates for each protein, compared with the biological replicates of negative control proteins, which do
not display rapid changes. The relative fold change is shown on the x axis using the log2 ratio MG132/DMSO (Heavy/Light). B, Rapidly depleted
proteins were analyzed for their response to the proteasome inhibitor MG132. The y axis shows the relative fold change for the RDPs using
the log2 ratio MG132/DMSO (Heavy/Light). The x axis shows the relative fold change for the RDPs using the log2 ratio cycloheximide/DMSO
(Medium/Light). Examples of previously uncharacterized proteins highlighted in this study are marked in red and proteins regarded as positive
controls are marked in green in both scatter plots. C, Immunoblotting of total cell lysates of U2OS cells after a time course of cycloheximide
exposure, either in the presence, or absence, of proteasome inhibition to examine protein degradation, (n  3). Arrowhead (filled white)
indicates the PRR11 band, arrowhead (filled black) indicates the MLF2 band, and asterisks mark nonspecific bands. D, Quantitation of the
PRR11 band from (C) with error bars indicating standard deviations (n  3). See also supplemental Fig. S6 for full blot images.
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FIG. 4. Analysis of PRR11 cell cycle regulation. A, An overview of the entire human PRR11 protein sequence including features and motifs
is shown (top), with the known ubiquitination site and phosphorylation sites indicated. An alignment of the C-terminal region of the PRR11
protein is shown (bottom), with various motifs and relevant known post-translational modifications to the human protein indicated. The
conservation of each sequence motif is indicated by a colored overlay. Red vertical bars in the protein sequence represent missing sequence
or gaps removed to show homology. The human PRR11 protein is highlighted in the alignment. B, Fluorescence-activated cell sorting of
asynchronous U2OS cells stained for DNA content and sorted into G1, S or G2/M-phases of the cell cycle based on the gates indicated, with
corresponding percentages of the total population. Immunoblotting of total cell lysates from the starting asynchronous cells and the sorted G1,
S and G2/M cells is shown, (n  2). Arrow head (filled white) indicates the PRR11 band, and an asterisk marks a nonspecific band.
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complex assembly, chromatin modification, and epidermis
development, were all significantly enriched in the U2OS RDP
subset.
To search for connections between the RDPs we used the
STRING database (39), which analyses multiple parameters
including co-expression, protein-protein interactions, and the
literature to identify links between proteins (Fig. 5C). Many
clusters were identified, of which several interesting networks
stand out. This includes the MRFAP1-MORF4L1-MORF4L2
cluster that we identified previously as a network of rapidly
degraded interacting proteins involved in chromatin regulation
(28), and the PLK1-TPX2-UBE2C cell cycle related cluster that
contains components associated with the anaphase promot-
ing complex (Fig. 5C).
A similar clustering analysis was performed on the RDPs
within each subcellular fraction (supplemental Fig. S5). This
showed several RDP clusters in the cytoplasmic fraction,
including a cell cycle related CDC20-UBE2C-UBE2S network
and an ABL1-WASL signaling network. As expected, the
membrane fraction contains most of the secreted proteins, as
well as a cell cycle related p21-CDK4 network. The nuclear
fraction highlights the MRFAP1-MORF4L1 network (28), the
mediator complex and a cell cycle related signaling network
containing Aurora B and PLK1 kinases. Of all the subcellular
fractions the cytoskeletal compartment has the fewest RDPs
and contains one main cluster comprising cytokeratins 1, 2,
and 10. These data show that overall many of the RDPs
identified are connected, either as part of multi-protein com-
plexes, or else as components of regulatory pathways.
DISCUSSION
We have used a comprehensive proteomic strategy, com-
bined with subcellular fractionation, to identify rapidly de-
graded proteins in specific compartments of U2OS osteosar-
coma cells. We have characterized the effects of inhibiting
either translation, or proteasome-mediated degradation, at
the proteome level. Based on analysis of more than 74,000
peptides from over 5000 human proteins, we identified pre-
viously uncharacterized, rapidly degraded proteins and pro-
teins whose degradation varied depending on subcellular lo-
calization. Using our workflow, the entire data set was
annotated for subcellular localization, apparent molecular
weight, abundance, and compartment specific degradation.
The response to proteasome inhibition was also analyzed at
the proteome level and showed a large-scale feedback inhi-
bition on protein synthesis. These data provide a valuable
resource detailing the spatial control of proteome degradation
and its regulation in the model human U2OS cell line. We
have created an Encyclopedia of Proteome Dynamics to
provide the community with convenient online access to
this, and other, large-scale proteomics data sets that we
have generated.
Several features of the proteomics strategy used here en-
hance the biological value of the resulting data set. For ex-
ample, because many proteins that are rapidly degraded oc-
cur in low abundance, size separation and analysis of subsets
of proteins helped to reduce the competition for detection
during LC-MS/MS. Subcellular fractionation not only assisted
with the detection efficiency, including for example membrane
proteins, but also provided insight into protein localization and
compartment specific degradation (40). This study provides
clear examples of specific proteins that are present in multiple
subcellular locations but that behave as RDPs only in a subset
of these locations. This is illustrated here both at the level of
individual RDPs and at the level of protein interaction net-
works. Detection of such spatial control relied on the use of
subcellular fractionation and was not apparent through the
analysis of whole cell lysates. Based on these data, we infer
that the spatial control of protein stability may be more com-
mon than previously realized. It will therefore be interesting in
future to compare this phenomenon in other cell types and
model organisms.
We believe that the strategy used here of cycloheximide
treatment to subsequently monitor protein degradation, is
complementary to studies that use the pulse-SILAC tech-
nique. Cycloheximide treatment has the advantage of avoid-
ing possible problems of metabolic labeling, such as delayed
incorporation of exogenously added amino acids at short time
points and complications with data analysis and interpretation
arising from the mixing of different pools of labeled and un-
labeled amino acids. On the other hand, blocking translation
with drug treatment may result in indirect effects on the pro-
teome that may affect cell physiology and distort proteome
dynamics. Therefore we regard both approaches as valid
methods to measure protein stability and comparing the re-
sulting data sets is particularly useful, as demonstrated by our
comparison of the current cycloheximide-based analysis with
FIG. 5. Computational analysis of the rapidly degraded proteins. A, Data derived from the Encyclopedia of Proteome Dynamics (EPD) is
shown. The EPD database, which includes the entire data set presented in this study, is freely accessible at http://www.peptracker.com/
encyclopediaInformation/. B, The analysis of enriched biological processes within the RDPs using the DAVID database (48). The y axis indicates
the EASE score (-log10 transformed) for each GO term enriched in the RDP data set versus the human proteome, with the p  0.01 cut-off
indicated by a dotted red line. The x axis shows the number of RDPs associated with each GO term (biological process). The size of bubble
associated with each GO term increases with increasing frequency of that term in the human proteome. Colors indicate related GO terms.
C, The analysis of networks within the RDPs using the STRING database. Each protein is represented by a node and proteins without
connections are not shown. Lines between nodes indicate a connection such as experimental interaction (pink), co-expression (black),
interaction databases (blue), literature (green), and homology (purple). Kmeans clustering has been used to highlight sub-networks within the
RDP data set with common coloring of these nodes.
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previous large scale pulse SILAC studies (see supplemental
Table S3).
A particularly striking finding of this study on U2OS cells
was that inhibition of the proteasome for 6 h did not cause an
increase in the abundance of almost any of the 5000 pro-
teins identified. These findings are consistent with two recent
reports that showed similar effects in either HCT116, or in
HeLa cells, i.e. that most proteins did not substantially change
in abundance after proteasome inhibition (37, 41). In our
study, even with the subset of RDPs, whose abundance
would be expected to increase the most if they are targets for
proteasome-mediated degradation, little or no change was
observed after treatment with MG132. Our analysis, however,
confirmed that the MG132 treatment effectively blocked the
proteasome and led to an increased level of K48-linked ubiq-
uitin and decreased levels of histone-ubiquitin conjugates.
Although some low abundance proteins that increase after
proteasome inhibition may be missing from these data sets,
(e.g. p53), nonetheless the data indicate that most proteins do
not accumulate when the proteasome is blocked.
This seems paradoxical, because many of the RDPs iden-
tified in our study appear to be proteasome targets. We pro-
pose that the resolution of this paradox is provided by our
current proteomic data showing that proteasome inhibition
induces the UPR and thereby causes a global inhibition of
translation. In addition, we observed increased abundance of
phospho-serine51 on eIF2alpha after MG132 treatment.
These observations are summarized in the model shown in
Fig. 6. This is consistent with the observations of Jiang and
Wek (42), who showed that inhibition of the proteasome leads
to phosphorylation of the eukaryotic initiation factor eIF2alpha
at ser51 and a reduction in translation. This phosphorylation
event occurs in response to multiple forms of cellular stress
and results in a broad inhibition of translation by reducing the
delivery of Met-tRNAi
Met to the ribosome.
What is the source of the unfolded proteins in this model?
Previous studies have shown that the ribosome does not
display 100% fidelity during translation and suggest up to
30% of translated proteins may be non-native “defective ri-
bosomal products” (DRiPs) (43). This proportion of DRiPs is
likely to vary, e.g. under different growth conditions and cell
types. Under normal conditions, the DRiPs will be rapidly
ubiquitinylated and degraded by the proteasome. In the pres-
ence of proteasome inhibitors, when these non-native pro-
teins cannot be degraded by the ubiquitin-proteasome sys-
tems normally used for their destruction (44), they will
accumulate over time and trigger the UPR. This is consistent
with our present data, showing that a variety of proteins
indicative of the UPR are up-regulated following inhibition of
the proteasome. As illustrated in the model (Fig. 6), inhibition
of the proteasome thus causes proteome-wide effects be-
yond simply blocking substrate degradation, because of the
FIG. 6. Model for proteome-wide responses after translation inhibition or proteasome inhibition. The ribosome produces both native
protein and nonnative protein. Native protein may be degraded by mechanisms that may differ depending on subcellular localization (indicated
by the gray arrows). Cycloheximide treatment allows us to observe this depletion as a decreased abundance of a protein over time. Under
normal conditions the nonnative protein is quickly ubiquitinated and degraded by the proteasome. Proteasome inhibition by MG132 treatment
blocks the degradation of both native proteins and nonnative proteins. This induces a build-up of nonnative protein that causes an unfolded
protein response. One outcome of this response to MG132 is the inhibition of protein synthesis by eIF-2 pSer51 phosphorylation. Therefore,
because MG132 simultaneously blocks the proteasome and protein synthesis, we observe very few proteins increasing in abundance after
proteasome inhibition and only the subset of RDPs depleted by nonproteasomal mechanisms decrease in abundance.
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complex feedback inhibition of translation. We note that, as
shown in the model, other pathways affecting protein stability
and cell physiology, such as autophagy, can also be triggered
by proteasome inhibition and the UPR. However, the contri-
bution of other pathways was not addressed directly in this
study and will be an interesting topic for future analysis.
Bioinformatics analysis indicated that the RDPs we identi-
fied were enriched for specific GO terms (Fig. 5B), indicating
that the control of protein stability may be particularly impor-
tant for regulatory pathways associated with these GO terms.
These terms included “mitosis” and “regulation of cell cycle,”
processes in which targeted protein degradation is known to
be critical. In addition, our analysis showed that APC/C and
FBXW7-SCF binding motifs, which are used in the G1-phase
of the cell cycle, were associated with many RDPs. This
further substantiates the link between protein stability and cell
cycle and correlates with the fact that the majority of the
asynchronous U2OS cells in our SILAC screen would be in G1
phase. It is interesting that despite the intensive previous
analysis of cell cycle regulated proteins, this study, focusing
on rapidly degraded proteins, has identified new examples,
such as PRR11. Our analysis showed that PRR11 abundance
is regulated across the cell cycle. This regulation is likely
mediated by the conserved APC/C and FBXW7-SCF targeting
motifs in the C terminus of the protein (Fig. 4A). Therefore, in
both late mitotic and G1-phase cells, the PRR11 protein may
be targeted for degradation by both the APC/C and FBXW7-
SCF complexes.
In addition to cell cycle and mitosis, the set of RDPs iden-
tified also highlighted GO terms associated with processes in
which the role of targeted protein degradation is less well
established. This included highly significant enrichment for
the GO terms, “chromatin organization” and “chromatin mod-
ification,” both of which had multiple protein examples. Other
related processes highlighted included “cellular response to
stress” and “response to DNA damage stimulus.” The enrich-
ment of the GO term “epidermis development” is also inter-
esting and may reflect the mesenchymal origin of the U2OS
cell line. We suggest it will be informative in future to investi-
gate further the potential role of targeted protein degradation
mechanisms in these processes.
As well as identifying likely proteasome substrates, our
global analysis has also indicated RDPs that are likely to be
either degraded by proteasome-independent mechanisms, or
else secreted. For example, CHCHD2 is a mitochondrial pro-
tein that has been shown previously to regulate oxidative
phosphorylation (45). Our data indicate that CHCHD2 was not
protected from degradation by proteasome inhibition and
therefore must be degraded by other means such as through
the mitochondrial degradation pathways of the Clp, Lon, or
AAA complexes (46). Proteasome-independent degradation
will also be needed for depletion of many membrane proteins
and proteins targeted for destruction by autophagy, which
uses lysosomal proteases (47). Our RDP data set includes
likely examples of secreted proteins, e.g. collagens and pro-
teins dependent on lysosomal degradation, e.g. GOLM1. This
supports the view that this data set provides a representative
overview of RDPs in human U2OS cells.
In summary, this study provides a resource identifying both
global and compartment specific rapidly degraded proteins in
U2OS cells, many of which are previously uncharacterized go
to sleep. We also document the proteome-wide effects re-
sulting from the negative feedback on translation induced by
proteasome inhibition and propose a model for the mecha-
nism responsible. The bioinformatics analysis of RDPs has
highlighted biological processes in which the control of pro-
tein degradation is likely to play an important role. An inter-
esting avenue for future research would be to examine how
protein degradation differs between normal and transformed
cells, as many proteins involved in cell proliferation, chromatin
regulation, and DNA damage repair may be differentially reg-
ulated between these cell states.
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